Asia Pacific Protein Expression Market Report and Forecast 2024-2032

The global protein expression market size was valued at USD 3 billion in 2023, with Asia Pacific holding a significant market share. The market is driven by the increased protein-based research and development activities. It is expected to grow at a CAGR of 11.10% during the forecast period of 2024-2032, with the values likely to attain USD 4.9 billion by 2032.

Key Takeaways

• Recent studies suggest that 80% of the population aged 60 or above in China is affected by at least one chronic disease. The rising prevalence of such chronic conditions is expected to fuel market growth for protein expression systems.
• One of the major Asia Pacific protein expression market trends is increased investment in biologics manufacturing facilities, which is likely to stimulate technological advancement and innovation in protein expression technologies. In November 2023, an Indian CDMO Aragen Life Sciences announced the confirmation of USD 30 million for setting up a biologics manufacturing site in Bengaluru (India) to boost its bioproduction capabilities including the production of therapeutic proteins.
• In the Asia Pacific region, the rising demand for biologic drugs, including monoclonal antibodies and recombinant proteins, owing to the growing need for targeted therapeutics is expected to elevate market value in the coming years.

Asia Pacific Protein Expression Market Analysis

Protein expression can be defined as a process in which proteins are produced, modified, and regulated in living organisms. Protein expression technologies can be utilized to synthesize therapeutic proteins, antibodies, and other biologics for treating various diseases. Such technologies are also employed in the development and production of vaccines against infectious diseases. The increased application of protein expression systems to facilitate drug development, disease diagnosis, and personalized medicine, is significantly contributing to the Asia Pacific protein expression market growth.

In Asia Pacific, the burden of chronic diseases such as cancer, cardiovascular diseases, and diabetes, is increasing rapidly which can be attributed to the growing aging population, sedentary lifestyle, and environmental factors, among others. Recent studies suggest that 80% of the population aged years 60 or above in China is affected by at least one chronic disease. To manage these chronic conditions, effective treatment options in the form of monoclonal antibodies, recombinant proteins, and other biologics, are required. Protein expression systems are an essential component in the production of these therapeutic proteins. Thus, the rising prevalence of chronic diseases is expected to fuel the Asia Pacific protein expression market demand in the forecast period.

One of the major market trends is increased investment in biologics manufacturing facilities, which is likely to stimulate technological advancement and innovation in protein expression technologies. In November 2023, an India-based contract development and manufacturing organization Aragen Life Sciences announced the confirmation of USD 30 million for setting up a biologics manufacturing site in Bengaluru (India) to boost its bioproduction capabilities. The facility, spanning over 160,000 square feet, is also set to develop and produce fusion proteins as well as therapeutic proteins. Such substantial investments are poised to expand the capacity for protein expression and production, thereby augmenting the Asia Pacific protein expression market share.

The market is witnessing an increased demand for biologic drugs, including monoclonal antibodies and recombinant proteins in the Asia Pacific region, owing to the rising prevalence of chronic diseases and the need for targeted therapeutics. This directly impacts the market dynamics for protein expression technologies as they are essential to produce biologics. Further, the rising healthcare expenditures, advancements in biotechnology, and increased investment in research infrastructure are anticipated to accelerate market growth in the forecast period.

Asia Pacific Protein Expression Market Segmentation

Market Breakup by Product

• Expression Vectors
• Competent Cells
• Reagents
• Instruments
• Services

Market Breakup by Application

• Industrial
• Research
• Therapeutic

Market Breakup by System Type

• Mammalian Cell Expression System
• Yeast Cell Expression System
• Insect Cell Expression System

Market Breakup by End User

• Academic Research
• Contract Research Organizations
• Pharmaceutical and Biotechnology Companies

Market Breakup by Country

• China
• Japan
• India
• ASEAN
• Australia
• Others

Asia Pacific Protein Expression Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Merck KGaA
• Thermo Fisher Scientific Inc.
• GenScript Biotech Corporation
• Agilent Technologies, Inc.
• Takara Bio Inc.
• Bio-Rad Laboratories, Inc.
• QIAGEN
• Promega Corporation
• GE Healthcare
• Bioneer Corporation

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

What is the Asia Pacific protein expression market forecast outlook for 2024-2032?
The Asia Pacific protein expression market is expected to be driven by the rising demand for the global protein expression market, which is anticipated to grow at a CAGR of 5.40% during the forecast period of 2024-2032 and is likely to reach a market value of USD 4.9 billion by 2032.

What are the major factors aiding the Asia Pacific protein expression market demand?
The rising healthcare expenditures and growing prevalence of chronic diseases are fuelling the demand for the market.

What are the major Asia Pacific protein expression trends?
One of the significant trends in the market is the increased investment in biologics manufacturing facilities which is likely to stimulate technological advancement and innovation in protein expression technologies. In November 2023, an Indian-based CDMO Aragen Life Sciences announced the confirmation of USD 30 million for setting up a biologics manufacturing site in Bengaluru (India) to boost its bioproduction capabilities including the production of therapeutic proteins.

What is the market segmentation based on the product?
Based on the product, the market is segmented into expression vectors, competent cells, reagents, instruments, and services.

What is the market breakup by system type?
By system type, the market is divided into mammalian cell expression system, yeast cell expression system, and insect cell expression system.

What are the major end users of the market?
End users of the market are academic research, contract research organizations, and pharmaceutical & biotechnology companies.

What are the applications of protein expression in the market?
Major applications in the market include industrial, research, and therapeutic.

What is the market segmentation by countries?
The market segmentation by countries includes China, Japan, India, ASEAN, and Australia, among others.

Who are the key players involved in the Asia Pacific protein expression market?
The key players in the market are Merck KGaA, Thermo Fisher Scientific Inc., GenScript Biotech Corporation, Agilent Technologies, Inc., Takara Bio Inc., Bio-Rad Laboratories, Inc., QIAGEN, Promega Corporation, GE Healthcare, and Bioneer Corporation.


This product will be delivered within 5-7 business days.